Thailand will launch its Covid-19 vaccination program on Monday, which focuses on the Oxford / AstraZeneca aerated glass produced by Siam Bioscience, owned by King Maha Vajiralongkorn, which has never produced a vaccine before.
The partnership is of great interest to both the government of Prayut Chan-ocha, which is facing a public outcry over the growing anger of business, and the AstraZeneca, which has chosen Thailand as its manufacturing hub in Southeast Asia.
Siam Bioscience will produce 200 million doses of coronavirus inhaler, including for export.
Thailand is fighting a wave of infections about 2,000-4,000 reports of new cases per day, the highest since the epidemic began.
Like its regional peers Vietnam և: Taiwan, the kingdom eliminated Covid-19 infections in 2020. The cause of the increase is the more contagious versions of the coronavirus, which quickly spread to markets, prisons, and labor camps.
But Siam Bioscience has shown signs of production delays. Philippines he said Last week, the first batch of 17 million doses expected from Thailand was delayed ի reduced in size.
Separately, the Rural Physicians Association of Thailand claims that the government was importing 500,000 doses of AstraZeneca vaccine from South Korea to make up for the shortfall. Some Thais said they had been told they could expect vaccinations in June, but later said they had been delayed.
Last week the Thai government received delivery The first of 1.8 million doses of AstraZeneca bite, the first of 6 million vaccines planned this month. It claims the launch is on schedule, but a government spokesman declined to answer the Financial Times’ question about whether it would use clasps imported from South Korea alongside locally produced ones. Siam Bioscience declined to comment, and AstraZeneca’s Thailand office did not respond to a request for comment.
Last week, the Thai Enquirer, an openly online publication, called Siam Biosense “an international disgrace.”
“Even Serum Institute in India It has problems, so it would be wrong to expect first-time manufacturer Siam Bioscience to run smoothly like silk, ”said Pavida Pananond, an international business professor at Tammasat Business School. “But AstraZeneca could have done a lot more by being a priority.”
As the number of infections increased earlier this year, the Thai government has been accused of relying too heavily on a single vaccine made by the first vaccine manufacturer. It has recently been moved to supply of porous by alternative suppliers, including Sinovac, a Chinese pharmaceutical company, BioNTech / Pfizer, Johnson & Johnson, and pharmaceutical companies.
The freedom of the Tayish to criticize the biology of Siam is constrained by the fact that: The billionaire king belongs to itIt is a criminal offense to make remarks that are considered insulting to the royal family.
Tanator HuangrongruangkitIn January, Thailand’s most prominent opposition figure was charged with high-profile “cybercrime” following online comments he called a “royal vaccine”.
The 69-year-old king of Thailand’s power and wealth have been unusually criticized by last year’s youth leaders Democracy is protesting,
Additional report by Ryn Jirenuwat in Bangkok
Follow on Twitter: @JohnReedwrites
Latest coronavirus news
Follow the FT’s live coverage, analysis of the global epidemic, and the rapidly emerging economic crisis. here:,